Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CAN008 prolongs overall survival in patients with newly diagnosed GBM characterized by high tumor mutational burden.

Biomedical journal - 1 Aug 2024

Chang Ian Yi-Feng, Tsai Hong-Chieh, Chen Chia-Hua, Chen Hsiu-Chi, Huang Chia-Wen, Cox Gerald F, Huang Fang-Min, Lin You-Yu, Chen Ko-Ting, Lin Ya-Jui, Wei Kuo-Chen

Abstract excerpt

BACKGROUND: A previous phase 1 dose-escalation study in Taiwan indicated CAN008 (asunercept) with standard concurrent chemoradiotherapy (CCRT) improved progression-free survival (PFS) in newly diagnosed glioblastoma (GBM) patients. This study evaluates the efficacy of CAN008 in promoting overall survival (OS) and identifies genetic alterations associated with treatment responses. METHODS: We compared OS of 5-year...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemoradiotherapy

Share to Cohort Studies

Share to Glioblastoma

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 37741340
DOI: 10.1016/j.bj.2023.100660
PMCID: PMC11340566

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CAN008 prolongs overall survival in patients with newly diagnosed GBM characterized by high tumor mutational burden.PMID 37741340Read ↗

Variability in Radiotherapy Outcomes Across Cancer Types: A Comparative Study of Glioblastoma Multiforme and Low-Grade GliomasSemantic proximity Read ↗

Genetic mutation patterns among glioblastoma patients in the Taiwanese population - insights from a single institution retrospective study.Semantic proximity Read ↗

Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide.Semantic proximity Read ↗

An in vivo model of glioblastoma radiation resistance identifies long noncoding RNAs and targetable kinasesSemantic proximity Read ↗

Experience about Chemoradiation treatment with or without Concurrent Tumor-Treating Fields (TTFields) in Newly Diagnosed Glioblastoma (GBM) Patients in ChinaSemantic proximity Read ↗

Induction Of XLF And 53BP1 Expression Is Associated With Temozolomide Resistance In Glioblastoma CellsSemantic proximity Read ↗

The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical dataSemantic proximity Read ↗

Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma.Semantic proximity Read ↗

miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferaseSemantic proximity Read ↗

EPIC-1042 as a potent PTRF/Cavin1–caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastomaSemantic proximity Read ↗

Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas: Results From a Prospective Study.Semantic proximity Read ↗

Prognostic Role of c-Met Overexpression in High Grade Glioma: a Meta-analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.